Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
A beginner-friendly intro to world stock dividend ETFs, covering basics like yields, diversification, and how to pick your first fund.
23,029 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
CrowdStrike has become a pillar in AI-era cybersecurity, but a 14% decline raises the question: is it a buy? This gui...
As energy demand grows, NuScale Power offers a potential long-term angle with small modular reactors. This guide expl...
Adobe stock is back in the spotlight as AI reshapes software. This guide explains what drives the buzz, how Adobe ear...
This week brought a notable rise for Corcept Therapeutics as investors reacted to a major catalyst. Learn what drove ...
In volatile markets, pulling back can create buying opportunities. This article highlights three growth stocks to buy...
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
Meta wants cloud could shake up the cloud market and test Amazon's AWS dominance. This guide breaks down what that co...
A quiet quantum player is showing real-world traction while the hype focuses on the big names. This analysis reveals ...
Nike is flirting with a comeback narrative as it gears up for June earnings. This guide breaks down what to watch, ho...
Imagine starting 2026 with $10,000 in intel. By mid-2026, that stake could push past $30,000 as the stock rallied. Th...
As 2026 unfolds, investors face a choice between StubHub's fast-growing digital ticketing platform and Build-A-Bear's...